CBD itself is not classified as a narcotic in Sweden, but full-spectrum products containing THC are illegal under the Supreme Court's 2019 ruling — regardless of concentration. Legal paths are raw hemp under 0.3% THC as a raw material, hemp seed foods (outside Novel Food) and THC-free CBD isolate.

In this guide

This guide gathers the answers step by step:

The question is common but rarely answered correctly. The short version: the most natural CBD oils are full-spectrum extracts. By definition, full-spectrum contains the entire cannabinoid profile—including trace amounts of THC—and it is this THC content that makes them illegal in Sweden according to the Supreme Court's 2019 ruling. The only legal full-spectrum alternative is the raw material itself—industrial hemp under 0.3% THC in its natural form.

This is not the whole picture. Hemp seed foods are outside the scope of Novel Food. THC-free CBD isolate falls outside the scope of the Supreme Court ruling. And the Kanavape judgment from the CJEU in 2020 puts Swedish interpretations under legal pressure from the EU. Here is the full official position as of May 2026—what courts and authorities have actually written, section by section.

The Dividing Line: Full-Spectrum Oil, Isolate, and Raw Hemp

The market offers CBD in several forms. Three of them dominate the product discussion—and a fourth, raw hemp, is seldom mentioned despite it being the only legal full-spectrum path in Sweden. For those who wish to delve deeper into extraction formats, we wrote a separate guide on full-spectrum, broad-spectrum, and isolate.

Full-spectrum CBD oil is an extract containing the entire cannabinoid profile from the hemp plant—CBD, CBN, CBG, terpenes—plus trace levels of THC, usually 0.1–0.3%. It is the format quality-conscious consumers often seek as it provides a natural 'entourage effect' from the interaction of cannabinoids.

Broad-spectrum CBD oil is marketed as THC-free. In practice, laboratory tests often show that trace amounts have slipped through the extraction process.

CBD isolate is pure cannabidiol that has been separated from other cannabinoids. Contains 0% THC.

Raw hemp — the plant itself in its unprocessed form. Industrial hemp under 0.3% THC naturally contains the entire cannabinoid profile and is legal as a raw material under EU agricultural legislation.

The 2019 Supreme Court ruling (Case B 177-19) specifically examined full-spectrum extracts with THC and established: a CBD preparation containing THC is classified as a narcotic preparation under the Psychotropic Convention, regardless of whether the concentration is 0.01% or 0.3%.

The conclusion is inconvenient for the market: the very format quality-conscious consumers often seek—natural full-spectrum oil—is the format prohibited by Swedish law. Broad-spectrum falls into the same legal risk category when tests reveal traces of THC. THC-free CBD isolate lies outside the scope of the ruling. The ruling specifically required the presence of THC to establish the narcotic classification.

Raw hemp as a raw material falls under the EU's agricultural definition under 0.3% THC; the 2019 Supreme Court ruling clarified, however, that the industrial-hemp exemption applies to the plant in cultivation and does not automatically extend to processed products. Helsama's own range combines two elements — ground raw hemp from Gotland (which naturally contains CBDA) and added CBD isolate that provides the active CBD form. The legal basis for sales is set out in the section What This Means for Helsama below. More on quality criteria in our in-depth guide Premium CBD in Sweden.

Four Categories — Four Sets of Regulations

CategoryExampleStatus
Industrial hemp under 0.3% THC (raw material)Hemp plant, flowers, hemp flourLegal under EU law
Hemp foodsSeeds, seed protein, seed powder, seed oilLegal food (outside Novel Food scope)
CBD isolate (0% THC)Powder with pure CBD isolateLegal; protected under Kanavape
CBD extract with trace THCFull-spectrum/broad-spectrum CBD oilNarcotic per Supreme Court 2019

Industrial Hemp under EU Law: The Legal Raw Material Stage

The EU's Common Agricultural Policy defines industrial hemp as hemp with a maximum of 0.3% THC—it is an agricultural crop, not a narcotic. Sweden applies this limit at the cultivation and raw material stages. Helsama's hemp comes exclusively from Gotland and falls within this definition.

At the Hemp Festival in Svedala on 28–29 June 2024, industrial hemp under 0.3% THC was sold and consumed openly with the approval of the municipality and the police. SVT interviewed Paul Nilsson, a police officer in Svedala municipality:

"I can't say it's positive, but it is approved, and we have been promised that it will proceed calmly."

This is a clear example of the reach of EU law at the cultivation and raw-material stage. How far that exemption extends into processed consumer products is a separate question — and precisely what the Supreme Court examined in 2019. It is a boundary every operator therefore needs to handle explicitly.

Hemp Foods: Outside the Scope of Novel Food

Hemp seeds and cold-pressed hemp seed oil are not Novel Food. They have a long history of food consumption in the EU and are sold as ordinary foods according to the Swedish Food Agency's Control Wiki. Hemp seeds are the largest commercial hemp category in Sweden, regulated like any other food. Helsama's seed range — unhulled, hulled and flavoured varieties — is available under diet & nutrition.

The Kanavape Judgment: EU Law Takes Precedence

The Swedish situation must be understood in the context of a broader European regulatory framework. The Kanavape judgment (CJEU C-663/18) of 19 November 2020 established three points:

  1. CBD is not a narcotic under EU law—it is neither psychoactive nor has any documented harmful effects.
  2. A Member State may not prohibit the sale of CBD legally produced in another Member State—this contravenes the principle of the free movement of goods (Article 34 TFEU).
  3. Any national restrictions must be proportionate, scientifically justified, and necessary for the protection of public health.

The judgment is binding on all 27 Member States and has not been overturned. France's Conseil d'État overturned the ban on CBD flowers in 2022 with a direct reference to Kanavape. When Italy enacted Decree Law 48/2025 in April 2025, which reclassified CBD as a narcotic, it came into open conflict with Kanavape—and is expected to be reviewed by the CJEU.

The 2019 Supreme Court ruling preceded Kanavape by 17 months and has not yet been tested against the principle of free movement in a Swedish legal proceeding. When such a review occurs, European proceedings point in a clear direction: national prohibitions on legally produced CBD are not sustainable.

Human Rights: A Parallel Playing Field

Alongside EU law, a rights-based track is emerging that challenges the prohibition model itself through international conventions. On 1 January 2026, the Norwegian organisation AROD (Alliance for Rights-Oriented Drug Policies) submitted coordinated petitions to seven UN bodies—including the High Commissioner for Human Rights, the Working Group on Arbitrary Detention, and the Special Rapporteurs on the right to health and on torture.

The argument is that broad cannabis prohibition violates the rights to liberty, health, a fair trial, and the right not to be arbitrarily detained. AROD describes prohibition as "a systemic failure driven by moral panic" with extensive legal and social harms.

The mechanism is strategically interesting: international legal recognition of a convention violation could force changes without going through slow national legislative processes. The petitions have recently been submitted and the outcome is uncertain—but legal circles point to this as one of the most important focus areas for the broader hemp and cannabis movements in the coming years.

The Swedish Medical Products Agency: Marketing Can Reclassify a Product

The Swedish Medical Products Agency is clear: a CBD product can be classified as a medicinal product based on how it is marketed, not solely on its contents. Claims of effects—even subtle ones—can move the product from the food or product category to the medicinal product category.

This requires approval as a medicinal product, which no CBD product on the Swedish consumer market has. The only CBD medicinal product with EU approval is Epidyolex, a prescription preparation for specific forms of epilepsy.

EFSA's Provisional Safety Level

For an in-depth review of EFSA's 2026 statement, read our analysis of the provisional safety level for CBD.

EFSA's scientific opinion of 9 February 2026 set a provisional safe level for CBD intake: 0.0275 mg per kilogram of body weight per day—for a 70 kg adult, this corresponds to around 2 mg of CBD per day. The level is provisional; the scientific evidence is still insufficient on several points, particularly long-term data.

The existence of a safety level does not mean a product is approved for sale—it is a prerequisite for the Novel Food process to proceed.

What This Means for Helsama

Helsama OÜ is registered in Estonia and processes hemp from Gotland. The range consists of two clearly separated product categories:

  • Hemp foods — unhulled, hulled and flavoured hemp seeds. Outside the scope of Novel Food, regulated as ordinary foods both in Sweden and the rest of the EU.
  • CBD products — Premium CBD Hemp, ground raw hemp from Gotland flowers (with natural seed content) together with added CBD isolate. Total THC under the EU's industrial-hemp threshold of 0.3%.

The legal basis for the CBD products does not lie in a Swedish exemption — Sweden has no quantitative THC threshold in its narcotics schedule, as the Supreme Court clarified in 2019. It rests on two components:

  1. Estonian regulatory approval. Helsama OÜ has been reviewed and approved to manufacture and sell the range in Estonia, under the conditions of total THC under 0.3% and no health claims in marketing.
  2. EU free movement of goods. The Kanavape judgment (CJEU C-663/18) established in 2020 that CBD is not a narcotic under EU law and that a Member State may not prevent the sale of CBD lawfully produced in another Member State. The ruling is binding and has not been overturned.

Helsama does not produce full-spectrum or broad-spectrum CBD oils — a deliberate choice to keep the range unequivocally on the right side of both the Estonian approval and EU law.

We make no claims about effects on the body or mind. This is a condition of the Estonian approval, and what EU Regulation 1924/2006 requires of every food product with a supplement or functional angle.

The legal issue also follows the science—the endogenous cannabinoid system is explained separately in the article on oxytocin and endocannabinoids.

Sources